Amarin Corporation PLC (AMRN) Receives Price Target

Amarin Corporation PLC (AMRN) : Average target price received by Amarin Corporation PLC (AMRN) is $6.83 with an expected standard deviation of $2.84. The most aggressive target on the stock is $10, whereas the most downbeat target is $5. 3 financial analysts are currently covering the stock.

Amarin Corporation PLC (AMRN) : 3 analysts are covering Amarin Corporation PLC (AMRN) and their average rating on the stock is 1, which is read as a Strong Buy. 3 equity analysts believe that the stock has a bright future and the price doesnt capture all of its upside, hence they rate the stock as a Strong Buy. A Zacks Investment Research rank of 2, which recommends a Buy affirms that they expect a large upside in the stock from the current levels.


Amarin Corporation PLC (NASDAQ:AMRN): The stock opened at $2.84 on Thursday but the bulls could not build on the opening and the stock topped out at $2.86 for the day. The stock traded down to $2.73 during the day, due to lack of any buying support eventually closed down at $2.79 with a loss of -0.36% for the day. The stock had closed at $2.80 on the previous day. The total traded volume was 4,247,581 shares.

Amarin Corporation plc (Amarin) is a biopharmaceutical company. The Company is engaged in the commercialization and development of therapeutics for cardiovascular health. Amarins lead product, Vascepa (icosapent ethyl) capsules, are used as an adjunct to diet to reduce triglyceride levels in adult patients with severe (triglyceride or TG over 500 milligrams per deciliter) hypertriglyceridemia. The Company sells Vascepa principally to various wholesalers, as well as regional wholesalers and specialty pharmacy providers, who in turn resell Vascepa to retail pharmacies for resale to patients and healthcare providers. Vascepa is available in the United States by prescription only. Amarin is also developing Vascepa for the treatment of patients with high (TG over 200 milligrams per deciliter and less than 500 milligrams per deciliter) triglyceride levels who are also on statin therapy for elevated low-density lipoprotein cholesterol (LDL-C) levels.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.